ATE361993T1 - Diagnose und behandlung von prostatakrebs - Google Patents
Diagnose und behandlung von prostatakrebsInfo
- Publication number
- ATE361993T1 ATE361993T1 AT01960979T AT01960979T ATE361993T1 AT E361993 T1 ATE361993 T1 AT E361993T1 AT 01960979 T AT01960979 T AT 01960979T AT 01960979 T AT01960979 T AT 01960979T AT E361993 T1 ATE361993 T1 AT E361993T1
- Authority
- AT
- Austria
- Prior art keywords
- hne
- gated
- voltage
- nucleic acid
- cancer
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 108091005461 Nucleic proteins Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0021617.6A GB0021617D0 (en) | 2000-09-02 | 2000-09-02 | Diagnosis and treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE361993T1 true ATE361993T1 (de) | 2007-06-15 |
Family
ID=9898761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01960979T ATE361993T1 (de) | 2000-09-02 | 2001-09-03 | Diagnose und behandlung von prostatakrebs |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20060166194A1 (de) |
| EP (1) | EP1313882B1 (de) |
| JP (1) | JP2004507254A (de) |
| AT (1) | ATE361993T1 (de) |
| AU (1) | AU2001282364A1 (de) |
| CY (1) | CY1107715T1 (de) |
| DE (1) | DE60128368T2 (de) |
| ES (1) | ES2288979T3 (de) |
| GB (1) | GB0021617D0 (de) |
| WO (1) | WO2002018637A2 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2443968A1 (en) * | 2001-04-12 | 2002-10-24 | Imperial College Innovations Limited | Diagnosis and treatment of cancer: i |
| AU2002251286A1 (en) * | 2001-04-12 | 2002-10-28 | Imperial College Innovations Limited | Diagnosis and treatment of cancer:ii |
| AU2005207002B2 (en) * | 2004-01-21 | 2011-03-17 | University Of Utah Research Foundation | Mutant sodium channel Nav1.7 and methods related thereto |
| ES2553264T3 (es) * | 2004-05-27 | 2015-12-07 | The Regents Of The University Of Colorado | Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer |
| US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
| US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
| US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
| EP2029779A4 (de) | 2006-06-14 | 2010-01-20 | Living Microsystems Inc | Verwendung hoch paralleler snp-genotypisierung zur fötalen diagnose |
| AU2008326497B2 (en) * | 2007-11-19 | 2014-02-13 | Genentech, Inc. | Compositions and methods for inhibiting tumor progression |
| GB0811360D0 (en) * | 2008-06-20 | 2008-07-30 | Imp Innovations Ltd | Methods |
| HUE031848T2 (en) | 2008-09-20 | 2017-08-28 | Univ Leland Stanford Junior | Non-invasive diagnosis of fetal aneuploidy by sequencing |
| US20120283116A1 (en) | 2009-09-11 | 2012-11-08 | Leppert Mark F | Mutant Sodium Channel Nav1.7 and Methods Related Thereto |
| SG10201601789TA (en) | 2011-03-16 | 2016-04-28 | Amgen Inc | Potent And Selective Inhibitors Of Nav1.3 And Nav1.7 |
| US9636418B2 (en) | 2013-03-12 | 2017-05-02 | Amgen Inc. | Potent and selective inhibitors of NAV1.7 |
| US10344060B2 (en) | 2013-03-12 | 2019-07-09 | Amgen Inc. | Potent and selective inhibitors of Nav1.7 |
| CN112513273A (zh) | 2018-06-22 | 2021-03-16 | 豪夫迈·罗氏有限公司 | 用于调节scn9a表达的寡核苷酸 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ296748A (en) * | 1994-11-02 | 1999-11-29 | Univ New York State Res Found | Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods |
| US6686193B2 (en) * | 2000-07-10 | 2004-02-03 | Vertex Pharmaceuticals, Inc. | High throughput method and system for screening candidate compounds for activity against target ion channels |
-
2000
- 2000-09-02 GB GBGB0021617.6A patent/GB0021617D0/en not_active Ceased
-
2001
- 2001-09-03 DE DE60128368T patent/DE60128368T2/de not_active Expired - Lifetime
- 2001-09-03 AT AT01960979T patent/ATE361993T1/de not_active IP Right Cessation
- 2001-09-03 ES ES01960979T patent/ES2288979T3/es not_active Expired - Lifetime
- 2001-09-03 US US10/362,747 patent/US20060166194A1/en not_active Abandoned
- 2001-09-03 WO PCT/GB2001/003940 patent/WO2002018637A2/en not_active Ceased
- 2001-09-03 AU AU2001282364A patent/AU2001282364A1/en not_active Abandoned
- 2001-09-03 JP JP2002522542A patent/JP2004507254A/ja active Pending
- 2001-09-03 EP EP01960979A patent/EP1313882B1/de not_active Expired - Lifetime
-
2007
- 2007-08-09 CY CY20071101073T patent/CY1107715T1/el unknown
- 2007-10-31 US US11/980,978 patent/US7759078B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001282364A1 (en) | 2002-03-13 |
| US20080145859A1 (en) | 2008-06-19 |
| DE60128368D1 (de) | 2007-06-21 |
| GB0021617D0 (en) | 2000-10-18 |
| US7759078B2 (en) | 2010-07-20 |
| WO2002018637A2 (en) | 2002-03-07 |
| WO2002018637A3 (en) | 2002-11-21 |
| JP2004507254A (ja) | 2004-03-11 |
| EP1313882A2 (de) | 2003-05-28 |
| CY1107715T1 (el) | 2013-04-18 |
| ES2288979T3 (es) | 2008-02-01 |
| DE60128368T2 (de) | 2008-01-10 |
| EP1313882B1 (de) | 2007-05-09 |
| US20060166194A1 (en) | 2006-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107715T1 (el) | Διαγνωση και αγωγη του καρκινου του προστατη | |
| WO2002083945A3 (en) | Diagnosis and treatment of cancer: i | |
| ATE353974T1 (de) | Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs | |
| MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
| DE60134995D1 (de) | Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden | |
| DE69933989D1 (de) | Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten | |
| EA200501772A1 (ru) | Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани | |
| BR0110091A (pt) | Composições e processos para terapia e diagnóstico de câncer de mama | |
| MXPA04000080A (es) | Metodos de diagnostico de cancer en la vejiga, composiciones y metodos de rastreo de moduladores de cancer en la vejiga. | |
| ATE266723T1 (de) | Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen | |
| WO2000052054A3 (en) | Antibodies for cancer therapy and diagnosis | |
| Seebauer et al. | Effects of cold physical plasma on oral lichen planus: an in vitro study (effects of CAP on OLP) | |
| ATE375389T1 (de) | Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen | |
| BRPI0407213A (pt) | Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados | |
| DE69920681D1 (de) | Humaner k+ ionenkanal und therapeutische verwendungen davon | |
| Schoser et al. | A large german kindred with cold‐aggravated myotonia and a heterozygous A1481D mutation in the SCN4A gene | |
| ATE390435T1 (de) | Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie | |
| DE60035857D1 (de) | Nukleinsäure- und aminosäuresequenzen von durch hämoglobin induzierbaren genen aus candida albicans und die verwendung dieser sequenzen in reagenzien zur diagnose von disseminierten candida albicans infektionen | |
| WO2001016158A3 (en) | Bridging integrator-2 (bin2) nucleic acid molecules and proteins and uses therefor | |
| WO2003084480A3 (en) | HAUSP-p53 INTERACTION AND USES THEREOF | |
| BR9910752A (pt) | Métodos e meios para prevenção de cáries e detecção de susceptibilidade | |
| Ferrari et al. | Nucleosomal structure as probed by H3 histone thiol reactivity: Conformation of H3 histone variants is differently affected by thiol group reagents | |
| ATE322553T1 (de) | Verfahren zur bestimmung des malignen zellezustands und verfahren zur behandlung | |
| MXPA03000980A (es) | Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas. | |
| ATE363075T1 (de) | Verfahren zur diagnose und behandlung von metastasen und dafür nützliche zusammensetzung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |